Publications:

---

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.

Cell Communication And Signaling : Ccs

Li, Yufeng Y; Mao, Tianyu T; Wang, Jing J; Zheng, Hongrui H; Hu, Ziyi Z; Cao, Pingping P; Yang, Suisui S; Zhu, Lingyun L; Guo, Shunyao S; Zhao, Xinfei X; Tian, Yue Y; Shen, Hua H; Lin, Fan F

Publication Date: 2023-04-11

Variant appearance in text: EGFR: M766Q

PubMed Link: 37041601

Variant Present in the following documents:

• Main text
• 12964_2023_Article_1082.pdf

View BVdb publication page

---

A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine.

Journal Of Clinical Medicine

Sattler, Martin M; Mambetsariev, Isa I; Fricke, Jeremy J; Tan, Tingting T; Liu, Sariah S; Vaidehi, Nagarajan N; Pisick, Evan E; Mirzapoiazova, Tamara T; Rock, Adam G AG; Merla, Amartej A; Sharma, Sunil S; Salgia, Ravi R

Publication Date: 2023-03-01

Variant appearance in text: EGFR: M766Q

PubMed Link: 36902723

Variant Present in the following documents:

• Main text
• jcm-12-01936.pdf

View BVdb publication page

---

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization.

Ebiomedicine

Sun, Yiting Y; Dong, Yiting Y; Liu, Xijuan X; Zhang, Yundi Y; Bai, Hua H; Duan, Jianchun J; Tian, Zhihua Z; Yan, Xiang X; Wang, Jie J; Wang, Zhijie Z

Publication Date: 2022-09

Variant appearance in text: EGFR: M766Q

PubMed Link: 35932642

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Emerging strategies to overcome resistance to third-generation EGFR inhibitors.

Journal Of Hematology & Oncology

Shi, Kunyu K; Wang, Guan G; Pei, Junping J; Zhang, Jifa J; Wang, Jiaxing J; Ouyang, Liang L; Wang, Yuxi Y; Li, Weimin W

Publication Date: 2022-07-15

Variant appearance in text: EGFR: M766Q

PubMed Link: 35840984

Variant Present in the following documents:

• Main text
• 13045_2022_Article_1311.pdf

View BVdb publication page

---

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

International Journal Of Molecular Sciences

Bertoli, Elisa E; De Carlo, Elisa E; Del Conte, Alessandro A; Stanzione, Brigida B; Revelant, Alberto A; Fassetta, Kelly K; Spina, Michele M; Bearz, Alessandra A

Publication Date: 2022-06-22

Variant appearance in text: EGFR: M766Q

PubMed Link: 35805940

Variant Present in the following documents:

• ijms-23-06936.pdf

View BVdb publication page

---

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review.

Frontiers In Oncology

Zhang, Hui H; Wang, Yong Y; Wu, Huaguo H; Zhou, Shizhen S; Li, Shuo S; Meng, Xiangji X; Tao, Rongjie R; Yu, Jinming J

Publication Date: 2022

Variant appearance in text: EGFR: M766Q

PubMed Link: 35494030

Variant Present in the following documents:

• Main text
• fonc-12-877279.pdf

View BVdb publication page

---

Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

Cancer Science

Koga, Takamasa T; Suda, Kenichi K; Mitsudomi, Tetsuya T

Publication Date: 2022-03

Variant appearance in text: EGFR: M766Q

PubMed Link: 34997674

Variant Present in the following documents:

• Main text
• CAS-113-815-s001.pdf
• CAS-113-815.pdf

View BVdb publication page

---

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.

Innovation (Cambridge (Mass.))

Du, Xiaojing X; Yang, Biwei B; An, Quanlin Q; Assaraf, Yehuda G YG; Cao, Xin X; Xia, Jinglin J

Publication Date: 2021-05-28

Variant appearance in text: EGFR: M766Q

PubMed Link: 34557754

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.

Innovation (New York, N.Y.)

Du, Xiaojing X; Yang, Biwei B; An, Quanlin Q; Assaraf, Yehuda G YG; Cao, Xin X; Xia, Jinglin J

Publication Date: 2021-05-28

Variant appearance in text: EGFR: M766Q

PubMed Link: 34557754

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

---

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.

British Journal Of Cancer

Conlon, Neil T NT; Kooijman, Jeffrey J JJ; van Gerwen, Suzanne J C SJC; Mulder, Winfried R WR; Zaman, Guido J R GJR; Diala, Irmina I; Eli, Lisa D LD; Lalani, Alshad S AS; Crown, John J; Collins, Denis M DM

Publication Date: 2021-03

Variant appearance in text: EGFR: M766Q

PubMed Link: 33473169

Variant Present in the following documents:

• 41416_2020_Article_1257.pdf

View BVdb publication page

---

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.

British Journal Of Cancer

Conlon, Neil T NT; Kooijman, Jeffrey J JJ; van Gerwen, Suzanne J C SJC; Mulder, Winfried R WR; Zaman, Guido J R GJR; Diala, Irmina I; Eli, Lisa D LD; Lalani, Alshad S AS; Crown, John J; Collins, Denis M DM

Publication Date: 2021-03

Variant appearance in text: EGFR: M766Q

PubMed Link: 33473169

Variant Present in the following documents:

• 41416_2020_Article_1257.pdf

View BVdb publication page

---

Liquid biopsies in non-small cell lung cancer management: what can we learn from methylation status and mutant allele frequencies?

Translational Lung Cancer Research

Castellano, Gina M GM; Pine, Sharon R SR

Publication Date: 2020-08

Variant appearance in text: EGFR: M766Q

PubMed Link: 32953473

Variant Present in the following documents:

• tlcr-09-04-951.pdf

View BVdb publication page

---

Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Pharmacology & Therapeutics

Meador, Catherine B CB; Hata, Aaron N AN

Publication Date: 2020-06

Variant appearance in text: EGFR: M766Q

PubMed Link: 32151666

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.

Theranostics

Garbuzenko, Olga B OB; Kuzmov, Andriy A; Taratula, Oleh O; Pine, Sharon R SR; Minko, Tamara T

Publication Date: 2019

Variant appearance in text: EGFR: M766Q

PubMed Link: 31754402

Variant Present in the following documents:

• thnov09p8362.pdf

View BVdb publication page

---

A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.

Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer

Castellano, Gina M GM; Aisner, Joseph J; Burley, Stephen K SK; Vallat, Brinda B; Yu, Helena A HA; Pine, Sharon R SR; Ganesan, Shridar S

Publication Date: 2019-11

Variant appearance in text: EGFR: M766Q

PubMed Link: 31254668

Variant Present in the following documents:

• Main text

View BVdb publication page

---